WallStSmart

Ascentage Pharma Group International (AAPG)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Ascentage Pharma Group International generates 77275% more annual revenue ($574.12M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -216.5%. AAPG earns a higher WallStSmart Score of 29/100 (F).

AAPG

Avoid

29

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.3Quality: 4.3
Piotroski: 2/9Altman Z: -4.15

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 7.3
Piotroski: 2/9Altman Z: 3.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AAPGUndervalued (+6.8%)

Margin of Safety

+6.8%

Fair Value

$26.39

Current Price

$21.66

$4.73 discount

UndervaluedFair: $26.39Overvalued

Intrinsic value data unavailable for RVMD.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AAPG1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
117.0%10/10

Revenue surging 117.0% year-over-year

RVMD1 strengths · Avg: 10.0/10
Altman Z-ScoreHealth
3.2710/10

Safe zone — low bankruptcy risk

Areas to Watch

AAPG4 concerns · Avg: 3.3/10
Price/BookValuation
10.4x4/10

Trading at 10.4x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-154.6%2/10

ROE of -154.6% — below average capital efficiency

RVMD4 concerns · Avg: 3.5/10
Price/BookValuation
17.4x4/10

Trading at 17.4x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : AAPG

The strongest argument for AAPG centers on Revenue Growth. Revenue growth of 117.0% demonstrates continued momentum.

Bull Case : RVMD

The strongest argument for RVMD centers on Altman Z-Score.

Bear Case : AAPG

The primary concerns for AAPG are Price/Book, EPS Growth, Piotroski F-Score.

Bear Case : RVMD

The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.

Key Dynamics to Monitor

AAPG profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

AAPG is growing revenue faster at 117.0% — sustainability is the question.

RVMD generates stronger free cash flow (-356M), providing more financial flexibility.

Bottom Line

AAPG scores higher overall (29/100 vs 24/100) and 117.0% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Ascentage Pharma Group International

HEALTHCARE · BIOTECHNOLOGY · USA

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company is headquartered in Suzhou, China.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?